Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 Immunotherapy

Abstract excerpt

Immune checkpoint inhibition (ICI) is clinically active against multiple cancers, including urothelial cancer at the non-muscle invasive, muscle-invasive, and metastatic stages. Despite this, large numbers of patients experience disease progression and relapse after treatment with ICI-containing regimens. Tumor antigen-specific T cells are critical to ICI response, however few studies have evaluated the breadth an...

Topics

Open a Topic to create a Post that cites this publication.

• CTLA-4 Antigen
• Hepatocyte Nuclear Factor 1-alpha
• Immune Checkpoint Inhibitors
• Programmed Cell Death 1 Receptor
• Receptors, Antigen, T-Cell
• RNA-Seq
• Single-Cell Analysis
• Vaccination

Identifiers and source

Literature Corpus work

253fd048-9202-5c0a-ba94-705aa103c4c9

DOI

10.64898/2026.05.20.726664